The Road So Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?

Overview

Journal J Pers Med

Date 2020 Nov 24

PMID 33228198

Citations 2

Authors

Ana Rita Simoes

Ceres Fernandez-Rozadilla

Olalla Maronas

Angel Carracedo

Affiliations

Soon will be listed here.

Abstract

In recent decades, survival rates in colorectal cancer have improved greatly due to pharmacological treatment. However, many patients end up developing adverse drug reactions that can be severe or even life threatening, and that affect their quality of life. These remain a limitation, as they may force dose reduction or treatment discontinuation, diminishing treatment efficacy. From candidate gene approaches to genome-wide analysis, pharmacogenomic knowledge has advanced greatly, yet there is still huge and unexploited potential in the use of novel technologies such as next-generation sequencing strategies. This review summarises the road of colorectal cancer pharmacogenomics so far, presents considerations and directions to be taken for further works and discusses the path towards implementation into clinical practice.

Citing Articles

Practical notes on the current ESMO consensus guidelines for the management of patients with metastatic colorectal cancer in resource-constrained environments of low- to middle-income countries.

Maurel J, Tamayo M, Pitargue R, Ong-Cornel A, Mehta P, Diouf D Oncology. 2023; .

PMID: 36958305 PMC: 10413786. DOI: 10.1159/000530275.

Pharmacogenetics to Avoid Adverse Drug Reactions.

Lopez-Fernandez L J Pers Med. 2022; 12(2).

PMID: 35207648 PMC: 8879652. DOI: 10.3390/jpm12020159.

References

Chua W, Goldstein D, Lee C, Dhillon H, Michael M, Mitchell P . Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer. 2009; 101(6):998-1004. PMC: 2743363. DOI: 10.1038/sj.bjc.6605239. View

Parmar S, Schumann C, Rudiger S, Boeck S, Heinemann V, Kachele V . Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. 2011; 13(2):181-8. DOI: 10.1038/tpj.2011.51. View

Lee K, Chang H, Han S, Oh D, Im S, Bang Y . Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol. 2013; 71(4):843-51. DOI: 10.1007/s00280-013-2075-3. View

Bins S, Basak E, El Bouazzaoui S, Koolen S, Oomen-de Hoop E, van der Leest C . Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. Br J Cancer. 2018; 118(10):1296-1301. PMC: 5959881. DOI: 10.1038/s41416-018-0074-1. View

Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A . Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. Clin Pharmacol Ther. 2017; 102(1):123-130. DOI: 10.1002/cpt.615. View

Apellaniz-Ruiz M, Lee M, Sanchez-Barroso L, Gutierrez-Gutierrez G, Calvo I, Garcia-Estevez L . Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res. 2014; 21(2):322-8. DOI: 10.1158/1078-0432.CCR-14-1758. View

Won H, Lee J, Park J, Park Y, Lim H, Kang W . Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2011; 118(11):2828-36. DOI: 10.1002/cncr.26614. View

Zaanan A, Dumont L, Loriot M, Taieb J, Narjoz C . A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant. Clin Pharmacol Ther. 2013; 95(2):136. DOI: 10.1038/clpt.2013.183. View

Popat S, Matakidou A, Houlston R . Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004; 22(3):529-36. DOI: 10.1200/JCO.2004.05.064. View

10.

Madi A, Fisher D, Maughan T, Colley J, Meade A, Maynard J . Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer. 2018; 102:31-39. DOI: 10.1016/j.ejca.2018.07.009. View

11.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

12.

Paoluzzi L, Singh A, Price D, Danesi R, Mathijssen R, Verweij J . Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004; 44(8):854-60. DOI: 10.1177/0091270004267159. View

13.

van Kuilenburg A, Hausler P, Schalhorn A, Tanck M, Proost J, Terborg C . Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet. 2012; 51(3):163-74. DOI: 10.1007/BF03257473. View

14.

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K . Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007; 17(7):497-504. DOI: 10.1097/FPC.0b013e328014341f. View

15.

Ribelles N, Lopez-Siles J, Sanchez A, Gonzalez E, Sanchez M, Carabantes F . A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab. 2008; 9(4):336-43. DOI: 10.2174/138920008784220646. View

16.

Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H . UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004; 75(6):501-15. DOI: 10.1016/j.clpt.2004.01.010. View

17.

van Staveren M, Guchelaar H, van Kuilenburg A, Gelderblom H, Maring J . Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013; 13(5):389-95. DOI: 10.1038/tpj.2013.25. View

18.

Li M, Seiser E, Baldwin R, Ramirez J, Ratain M, Innocenti F . ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2016; 18(1):35-42. PMC: 5432414. DOI: 10.1038/tpj.2016.75. View

19.

Cecchin E, DAndrea M, Lonardi S, Zanusso C, Pella N, Errante D . A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2012; 13(5):403-9. PMC: 3859145. DOI: 10.1038/tpj.2012.31. View

20.

Raymond E, Chaney S, Taamma A, Cvitkovic E . Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998; 9(10):1053-71. DOI: 10.1023/a:1008213732429. View